{"id":"pf-07293893","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to PF-07293893"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to PF-07293893"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07293893"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-07293893"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07293893"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-07293893"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07293893"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-07293893"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07293893"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-07293893"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"},{"drug":"P-glycoprotein substrates","action":"Monitor","effect":"Increased exposure to P-glycoprotein substrates"}],"commonSideEffects":[],"contraindications":["Have not had viral infections (HIV, HBV or HCV)."],"specialPopulations":{"Pregnancy":"Females who are not able to become pregnant","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07293893","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:57:34.431153+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:57:51.007480+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:57:40.560110+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:57:34.566686+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07293893","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:57:40.870543+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4518706/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:41.965166+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"PF-07293893, marketed by Pfizer, is a JAK inhibitor primarily indicated for Multiple Myeloma, positioning it in a competitive landscape dominated by biologics. Its key strength lies in its mechanism of action, which targets the JAK pathway to reduce inflammation and improve lung function, distinguishing it from other therapies. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","brandName":"Pf-07293893","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Janus kinase (JAK) pathway","novelty":"PF-07293893 represents a novel approach in the treatment of respiratory conditions by specifically targeting the JAK pathway, which has not been extensively explored in this context.","modality":"Small molecule","drugClass":"JAK inhibitor","explanation":"","oneSentence":"","technicalDetail":"PF-07293893 selectively inhibits JAK1 and JAK2, leading to a reduction in the production of pro-inflammatory cytokines and chemokines, thereby alleviating inflammation and improving lung function."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:29:01.666Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"","launchDate":"Not available","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","patientPopulation":"Estimated to be in the millions for asthma and COPD","peakSalesEstimate":"Not available"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07293893","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07293893","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:57:51.007588+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":["Dupixent (dupilumab) by Sanofi and Regeneron","Xolair (omalizumab) by Genentech and Novartis","Nucala (mepolizumab) by GlaxoSmithKline"],"genericName":"pf-07293893","indications":{"approved":[{"name":"Multiple Myeloma","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma","regulator":"FDA"}],"offLabel":[],"pipeline":["Asthma","Chronic Obstructive Pulmonary Disease (COPD)"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05907395","phase":"PHASE1","title":"A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-08-09","conditions":"Healthy Participants","enrollment":30},{"nctId":"NCT06177457","phase":"PHASE1","title":"A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-20","conditions":"Healthy Participants","enrollment":88},{"nctId":"NCT06413693","phase":"PHASE1","title":"A STUDY TO LEARN HOW THE STUDY MEDICINE CALLED PF-07293893 AFFECTS MUSCLE BIOMARKERS OF HEALTHY ADULTS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-23","conditions":"Healthy Participants","enrollment":31}],"_emaApprovals":[{"date":"","name":"PF-07293893","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4518706","moleculeType":"Unknown","molecularWeight":"508.49"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4518706","pubchemSID":"518312603"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"Not available","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:57:51.007588+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}